Prostatype Genomics AB announces today that the company is changing its Certified Adviser to Tapper Partners AB.

Prostatype Genomics AB has entered into an agreement with Tapper Partners AB regarding the role as Certified Adviser.

Tapper Partners AB will assume the role of Certified Adviser on August 15, 2025. Until then, DNB Carnegie Investment Bank AB will continue to act as the company's Certified Adviser.

Contacts
For further information about Prostatype Genomics, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 73 049 77 01.
e-mail: fredrik.rickman@prostatypegenomics.com

Certified Advisor
DNB Carnegie Investment Bank AB
Telephone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se

About Us
About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

Attachments
Prostatype Genomics AB changes Certified Adviser to Tapper Partners AB

Läs mer på MFN